Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 165105, 9 pages
http://dx.doi.org/10.1155/2015/165105
Review Article

Switching the Sphingolipid Rheostat in the Treatment of Diabetes and Cancer Comorbidity from a Problem to an Advantage

1The University of Queensland, The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, QLD, Australia
2The Centenary Institute, Newtown, NSW, Australia
3Discipline of Dermatology, University of Sydney, Camperdown, NSW, Australia
4School of Medical and Molecular Biosciences, University of Technology Sydney, Ultimo, NSW 2007, Australia
5Sydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia

Received 17 July 2014; Accepted 16 October 2014

Academic Editor: Anandwardhan Hardikar

Copyright © 2015 Nikolas K. Haass et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Danaei, M. M. Finucane, Y. Lu et al., “National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants,” The Lancet, vol. 378, no. 9785, pp. 31–40, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. WHO, Global Status Report on Noncommunicable Diseases 2010, WHO, Geneva, Switzerland, 2011.
  3. J. Ferlay, I. Soerjomataram, M. Ervik et al., GLOBOCAN 2012 v1.0, IARC Cancer Base No. 11, Cancer Incidence and Mortality Worldwide, 2012.
  4. F. Bray, J.-S. Ren, E. Masuyer, and J. Ferlay, “Global estimates of cancer prevalence for 27 sites in the adult population in 2008,” International Journal of Cancer, vol. 132, no. 5, pp. 1133–1145, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Sen, Y. He, D. Koya, and K. Kanasaki, “Cancer biology in diabetes,” Journal of Diabetes Investigation, vol. 5, no. 3, pp. 251–264, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. S. K. Garg, H. Maurer, K. Reed, and R. Selagamsetty, “Diabetes and cancer: two diseases with obesity as a common risk factor,” Diabetes, Obesity and Metabolism, vol. 16, no. 2, pp. 97–110, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. J. Khandekar, P. Cohen, and B. M. Spiegelman, “Molecular mechanisms of cancer development in obesity,” Nature Reviews Cancer, vol. 11, no. 12, pp. 886–895, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Giovannucci, D. M. Harlan, M. C. Archer et al., “Diabetes and cancer: a consensus report,” Diabetes Care, vol. 33, no. 7, pp. 1674–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. B. B. Barone, H.-C. Yeh, C. F. Snyder et al., “Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis,” The Journal of the American Medical Association, vol. 300, no. 23, pp. 2754–2764, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Noto, A. Goto, T. Tsujimoto, K. Osame, and M. Noda, “Latest insights into the risk of cancer in diabetes,” Journal of Diabetes Investigation, vol. 4, no. 3, pp. 225–232, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Jalving, J. A. Gietema, J. D. Lefrandt et al., “Metformin: taking away the candy for cancer?” European Journal of Cancer, vol. 46, no. 13, pp. 2369–2380, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Maceyka, K. B. Harikumar, S. Milstien, and S. Spiegel, “Sphingosine-1-phosphate signaling and its role in disease,” Trends in Cell Biology, vol. 22, no. 1, pp. 50–60, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J.-P. Truman, M. García-Barros, L. M. Obeid, and Y. A. Hannun, “Evolving concepts in cancer therapy through targeting sphingolipid metabolism,” Biochimica et Biophysica Acta, vol. 1841, no. 8, pp. 1174–1188, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. L. A. Heffernan-Stroud and L. M. Obeid, “Sphingosine kinase 1 in cancer,” Advances in Cancer Research, vol. 117, pp. 201–235, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Plano, S. Amin, and A. K. Sharma, “Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors,” Journal of Medicinal Chemistry, vol. 7, no. 13, pp. 5509–5524, 2014. View at Google Scholar
  16. C. R. Bruce, S. Risis, J. R. Babb et al., “Overexpression of sphingosine kinase 1 prevents ceramide accumulation and ameliorates muscle insulin resistance in high-fat diet-fed mice,” Diabetes, vol. 61, no. 12, pp. 3148–3155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. M. M. Ma, J. L. Chen, G. G. Wang et al., “Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice,” Diabetologia, vol. 50, no. 4, pp. 891–900, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. A. Hannun and L. M. Obeid, “Principles of bioactive lipid signalling: lessons from sphingolipids,” Nature Reviews Molecular Cell Biology, vol. 9, no. 2, pp. 139–150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Olivera and S. Spiegel, “Sphingosine-1-phosphate as second messenger in cell proliferation induced by PDGF and FCS mitogens,” Nature, vol. 365, no. 6446, pp. 557–560, 1993. View at Publisher · View at Google Scholar · View at Scopus
  20. J. R. van Brocklyn, M.-J. Lee, R. Menzeleev et al., “Dual actions of sphingosine-1-phosphate: extracellular through the Gi- coupled receptor Edg-1 and intracellular to regulate proliferation and survival,” The Journal of Cell Biology, vol. 142, no. 1, pp. 229–240, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. “Report of the expert committee on the diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 26, supplement 1, pp. S5–S20, 2003.
  22. M. Cnop, N. Welsh, J.-C. Jonas, A. Jörns, S. Lenzen, and D. L. Eizirik, “Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities,” Diabetes, vol. 54, no. 2, pp. S97–S107, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Shao, Y. Yang, G. Yuan, M. Zhang, and X. Yu, “Signaling molecules involved in lipid-induced pancreatic beta-cell dysfunction,” DNA and Cell Biology, vol. 32, no. 2, pp. 41–49, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Newsholme, D. Keane, H. J. Welters, and N. G. Morgan, “Life and death decisions of the pancreatic β-cell: the role of fatty acids,” Clinical Science, vol. 112, no. 1-2, pp. 27–42, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Phielix and M. Mensink, “Type 2 diabetes mellitus and skeletal muscle metabolic function,” Physiology and Behavior, vol. 94, no. 2, pp. 252–258, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Johnson and M. Pollak, “Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes,” Diabetologia, vol. 53, no. 10, pp. 2086–2088, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Li and D. Kong, “Cancer risks from diabetes therapies: evaluating the evidence,” Pharmacology & Therapeutics, vol. 144, no. 1, pp. 71–81, 2014. View at Google Scholar
  28. L. Braccini, E. Ciraolo, M. Martini et al., “PI3K keeps the balance between metabolism and cancer,” Advances in Biological Regulation, vol. 52, no. 3, pp. 389–405, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Zoncu, A. Efeyan, and D. M. Sabatini, “mTOR: From growth signal integration to cancer, diabetes and ageing,” Nature Reviews Molecular Cell Biology, vol. 12, no. 1, pp. 21–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. K. A. Orr Gandy and L. M. Obeid, “Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1831, no. 1, pp. 157–166, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. N. J. Pyne and S. Pyne, “Sphingosine 1-phosphate and cancer,” Nature Reviews Cancer, vol. 10, no. 7, pp. 489–503, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. N. J. Pyne, F. Tonelli, K. G. Lim et al., “Targeting sphingosine kinase 1 in cancer,” Biochemical Society Transactions, vol. 40, no. 1, pp. 94–100, 2012. View at Publisher · View at Google Scholar
  33. Y. A. Hannun, C. R. Loomis, A. H. Merrill Jr., and R. M. Bell, “Sphingosine inhibition of protein kinase C activity and of phorbol dibutyrate binding in vitro and in human platelets,” The Journal of Biological Chemistry, vol. 261, no. 27, pp. 12604–12609, 1986. View at Google Scholar · View at Scopus
  34. S. Milstien and S. Spiegel, “Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics,” Cancer Cell, vol. 9, no. 3, pp. 148–150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Alemany, C. J. van Koppen, K. Danneberg, M. Ter Braak, and D. M. Zu Heringdorf, “Regulation and functional roles of sphingosine kinases,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 374, no. 5-6, pp. 413–428, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. H. J. Abuhusain, A. Matin, Q. Qiao et al., “A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis,” The Journal of Biological Chemistry, vol. 288, no. 52, pp. 37355–37364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. N. C. Hait, C. A. Oskeritzian, S. W. Paugh, S. Milstien, and S. Spiegel, “Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases,” Biochimica et Biophysica Acta, vol. 1758, no. 12, pp. 2016–2026, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Mendelson, T. Evans, and T. Hla, “Sphingosine 1-phosphate signalling,” Development, vol. 141, no. 1, pp. 5–9, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Rapizzi, M. L. Taddei, T. Fiaschi, C. Donati, P. Bruni, and P. Chiarugi, “Sphingosine 1-phosphate increases glucose uptake through trans-activation of insulin receptor,” Cellular and Molecular Life Sciences, vol. 66, no. 19, pp. 3207–3218, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Schüppel, U. Kürschner, U. Kleuser, M. Schäfer-Korting, and B. Kleuser, “Sphingosine 1-phosphate restrains insulin-mediated keratinocyte proliferation via inhibition of Akt through the S1P2 receptor subtype,” The Journal of Investigative Dermatology, vol. 128, no. 7, pp. 1747–1756, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Yagoub, M. R. Wilkins, A. J. Lay et al., “Sphingosine kinase 1 isoform-specific interactions in breast cancer,” Molecular Endocrinology, vol. 28, no. 11, pp. 1899–1915, 2014. View at Publisher · View at Google Scholar
  42. K. G. Lim, F. Tonelli, E. Berdyshev et al., “Inhibition kinetics and regulation of sphingosine kinase 1 expression in prostate cancer cells: functional differences between sphingosine kinase 1a and 1b,” The International Journal of Biochemistry & Cell Biology, vol. 44, no. 9, pp. 1457–1464, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Qi, J. Chen, A. Lay, A. Don, M. Vadas, and P. Xia, “Loss of sphingosine kinase 1 predisposes to the onset of diabetes via promoting pancreatic β-cell death in diet-induced obese mice,” FASEB Journal, vol. 27, no. 10, pp. 4294–4304, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. W. L. Holland, J. T. Brozinick, L.-P. Wang et al., “Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance,” Cell Metabolism, vol. 5, no. 3, pp. 167–179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. C. F. Jessup, C. S. Bonder, S. M. Pitson, and P. T. H. Coates, “The sphingolipid rheostat: a potential target for improving pancreatic islet survival and function,” Endocrine, Metabolic and Immune Disorders: Drug Targets, vol. 11, no. 4, pp. 262–272, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. N. M. Hasan, M. J. Longacre, S. W. Stoker et al., “Sphingosine kinase 1 knockdown reduces insulin synthesis and secretion in a rat insulinoma cell line,” Archives of Biochemistry and Biophysics, vol. 518, no. 1, pp. 23–30, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. W. L. Holland, R. A. Miller, Z. V. Wang et al., “Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin,” Nature Medicine, vol. 17, no. 1, pp. 55–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Tao, A. Sifuentes, and W. L. Holland, “Regulation of glucose and lipid homeostasis by adiponectin: effects on hepatocytes, pancreatic β cells and adipocytes,” Best Practice & Research: Clinical Endocrinology and Metabolism, vol. 28, no. 1, pp. 43–58, 2014. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Iwatsuka, A. Shino, and Z. Suzuoki, “General survey of diabetic features of yellow KK mice,” Endocrinologia Japonica, vol. 17, no. 1, pp. 23–35, 1970. View at Publisher · View at Google Scholar · View at Scopus
  50. O. Schnell, F. Cappuccio, S. Genovese, E. Standl, P. Valensi, and A. Ceriello, “Type 1 diabetes and cardiovascular disease,” Cardiovascular Diabetology, vol. 12, no. 1, article 156, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. F. Paneni, J. A. Beckman, M. A. Creager, and F. Cosentino, “Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I,” European Heart Journal, vol. 34, no. 31, pp. 2436–2443, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. S. M. Grundy, I. J. Benjamin, G. L. Burke et al., “Diabetes and cardiovascular disease: a statement for healthcare professionals from the american heart association,” Circulation, vol. 100, no. 10, pp. 1134–1146, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Fioretto, P. M. Dodson, D. Ziegler, and R. S. Rosenson, “Residual microvascular risk in diabetes: unmet needs and future directions,” Nature Reviews Endocrinology, vol. 6, no. 1, pp. 19–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Paneni, S. Costantino, and F. Cosentino, “Insulin resistance, diabetes, and cardiovascular risk,” Current Atherosclerosis Reports, vol. 16, no. 7, article 419, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Li, S. Horke, and U. Forstermann, “Vascular oxidative stress, nitric oxide and atherosclerosis,” Atherosclerosis, vol. 237, pp. 208–219, 2014. View at Google Scholar
  56. P. Keul, K. Sattler, and B. Levkau, “HDL and its sphingosine-1-phosphate content in cardioprotection,” Heart Failure Reviews, vol. 12, no. 3-4, pp. 301–306, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. J. S. Karliner, “Sphingosine kinase regulation and cardioprotection,” Cardiovascular Research, vol. 82, no. 2, pp. 184–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. J. S. Karliner, “Sphingosine kinase and sphingosine 1-phosphate in the heart: a decade of progress,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1831, no. 1, pp. 203–212, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Penpargkul, T. Schaible, T. Yipintsoi, and J. Scheuer, “The effect of diabetes on performance and metabolism of rat hearts,” Circulation Research, vol. 47, no. 6, pp. 911–921, 1980. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Dahl-Jørgensen, J. R. Larsen, and K. F. Hanssen, “Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment?” Diabetologia, vol. 48, no. 8, pp. 1445–1453, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Fisher, “Diabetes and atherogenesis,” Heart, vol. 90, no. 3, pp. 336–340, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. R. Donnelly and K. R. Davis, “Type 2 diabetes and atherosclerosis,” Diabetes, Obesity and Metabolism, vol. 2, no. 1, pp. S21–S30, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Mestas and K. Ley, “Monocyte-endothelial cell interactions in the development of atherosclerosis,” Trends in Cardiovascular Medicine, vol. 18, no. 6, pp. 228–232, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. A. M. Whetzel, D. T. Bolick, and C. C. Hedrick, “Sphingosine-1-phosphate inhibits high glucose-mediated ERK1/2 action in endothelium through induction of MAP kinase phosphatase-3,” American Journal of Physiology: Cell Physiology, vol. 296, no. 2, pp. C339–C345, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. A. M. Whetzel, D. T. Bolick, S. Srinivasan et al., “Sphingosine-1 phosphate prevents monocyte/endothelial interactions in type 1 diabetic NOD mice through activation of the S1P1 receptor,” Circulation Research, vol. 99, no. 7, pp. 731–739, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. H. A. Khafaji and J. M. Suwaidi, “A typical presentation of acute and chronic coronary artery disease in diabetics,” World Journal of Cardiology, vol. 6, no. 8, pp. 802–813, 2014. View at Publisher · View at Google Scholar
  67. Z.-Q. Jin, J. S. Karliner, and D. A. Vessey, “Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation,” Cardiovascular Research, vol. 79, no. 1, pp. 134–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. D. A. Vessey, M. Kelley, L. Li, and Y. Huang, “Sphingosine protects aging hearts from ischemia/reperfusion injury: superiority to sphingosine 1-phosphate and ischemic pre- and post-conditioning,” Oxidative Medicine and Cellular Longevity, vol. 2, no. 3, pp. 146–151, 2009. View at Publisher · View at Google Scholar · View at Scopus
  69. D. A. Vessey, M. Kelley, L. Li et al., “Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury,” Medical Science Monitor, vol. 12, no. 10, pp. BR318–BR324, 2006. View at Google Scholar · View at Scopus
  70. C. S. Bonder, W. Y. Sun, T. Matthews et al., “Sphingosine kinase regulates the rate of endothelial progenitor cell differentiation,” Blood, vol. 113, no. 9, pp. 2108–2117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Yu, L. Yuan, M. Xu, Z. Zhang, and H. Duan, “Sphingosine kinase 1 improves cutaneous wound healing in diabetic rats,” Injury, vol. 45, no. 7, pp. 1054–1058, 2014. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Osawa, H. Uchinami, J. Bielawski, R. F. Schwabe, Y. A. Hannun, and D. A. Brenner, “Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-α,” The Journal of Biological Chemistry, vol. 280, no. 30, pp. 27879–27887, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. G. M. Kowalski, A. L. Carey, A. Selathurai, B. A. Kingwell, and C. R. Bruce, “Plasma sphingosine-1-phosphate is elevated in obesity,” PLoS ONE, vol. 8, no. 9, Article ID e72449, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Wang, L. Badeanlou, J. Bielawski, T. P. Ciaraldi, and F. Samad, “Sphingosine kinase 1 regulates adipose proinflammatory responses and insulin resistance,” American Journal of Physiology: Endocrinology and Metabolism, vol. 306, no. 7, pp. E756–E768, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Tous, R. Ferrer-Lorente, and L. Badimon, “Selective inhibition of sphingosine kinase-1 protects adipose tissue against LPS-induced inflammatory response in Zucker diabetic fatty rats,” The American Journal of Physiology, Endocrinology and Metabolism, vol. 307, no. 5, pp. E437–E446, 2014. View at Publisher · View at Google Scholar
  76. H. Furuya, M. Wada, Y. Shimizu et al., “Effect of sphingosine kinase 1 inhibition on blood pressure,” The FASEB Journal, vol. 27, no. 2, pp. 656–664, 2013. View at Publisher · View at Google Scholar · View at Scopus
  77. Z. Yin, L. Fan, L. Wei et al., “FTY720 protects cardiac microvessels of diabetes: a critical role of S1P1/3 in diabetic heart disease,” PLoS ONE, vol. 7, no. 8, Article ID e42900, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Janes, J. W. Little, C. Li et al., “The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1,” The Journal of Biological Chemistry, vol. 289, no. 30, pp. 21082–21097, 2014. View at Publisher · View at Google Scholar
  79. H. Guan, L. Song, J. Cai et al., “Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells,” PLoS ONE, vol. 6, no. 5, Article ID e19946, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. B. Xie, J. Shen, A. Dong, A. Rashid, G. Stoller, and P. A. Campochiaro, “Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization,” Journal of Cellular Physiology, vol. 218, no. 1, pp. 192–198, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. L. W. Maines, K. J. French, E. B. Wolpert, D. A. Antonetti, and C. D. Smith, “Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases,” Investigative Ophthalmology and Visual Science, vol. 47, no. 11, pp. 5022–5031, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. R. A. Sabbadini, “Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration,” British Journal of Pharmacology, vol. 162, no. 6, pp. 1225–1238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. B. Visentin, J. A. Vekich, B. J. Sibbald et al., “Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages,” Cancer Cell, vol. 9, no. 3, pp. 225–238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Mizugishi, T. Yamashita, A. Olivera, G. F. Miller, S. Spiegel, and R. L. Proia, “Essential role for sphingosine kinases in neural and vascular development,” Molecular and Cellular Biology, vol. 25, no. 24, pp. 11113–11121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. T. Lan, W. Liu, X. Xie et al., “Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells,” Molecular Endocrinology, vol. 25, no. 12, pp. 2094–2105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Fayyaz, J. Henkel, L. Japtok et al., “Involvement of sphingosine 1-phosphate in palmitate-induced insulin resistance of hepatocytes via the S1P2 receptor subtype,” Diabetologia, vol. 57, no. 2, pp. 373–382, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Fayyaz, L. Japtok, and B. Kleuser, “Divergent role of sphingosine 1-phosphate on insulin resistance,” Cellular Physiology and Biochemistry, vol. 34, pp. 134–147, 2014. View at Publisher · View at Google Scholar
  88. M. Bigaud, D. Guerini, A. Billich, F. Bassilana, and V. Brinkmann, “Second generation S1P pathway modulators: research strategies and clinical developments,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1841, no. 5, pp. 745–758, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Huwiler and J. Pfeilschifter, “New players on the center stage: sphingosine 1-phosphate and its receptors as drug targets,” Biochemical Pharmacology, vol. 75, no. 10, pp. 1893–1900, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Bandhuvula, Y. Y. Tam, B. Oskouian, and J. D. Saba, “The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity,” The Journal of Biological Chemistry, vol. 280, no. 40, pp. 33697–33700, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. N. C. Kaneider, J. Lindner, C. Feistritzer et al., “The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor,” The FASEB Journal, vol. 18, no. 11, pp. 1309–1311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. V. Brinkmann, M. D. Davis, C. E. Heise et al., “The immune modulator FTY720 targets sphingosine 1-phosphate receptors,” Journal of Biological Chemistry, vol. 277, no. 24, pp. 21453–21457, 2002. View at Publisher · View at Google Scholar · View at Scopus
  93. V. A. Blaho and T. Hla, “An update on the biology of sphingosine 1-phosphate receptors,” The Journal of Lipid Research, vol. 55, no. 8, pp. 1596–1608, 2014. View at Google Scholar
  94. I. Cristobal, R. Manso, and R. Rincon, “PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential,” Molecular Cancer Therapeutics, vol. 13, no. 4, pp. 938–947, 2014. View at Publisher · View at Google Scholar
  95. P. Neviani, R. Santhanam, J. J. Oaks et al., “FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia,” The Journal of Clinical Investigation, vol. 117, no. 9, pp. 2408–2421, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Nagahashi, N. C. Hait, M. Maceyka et al., “Sphingosine-1-phosphate in chronic intestinal inflammation and cancer,” Advances in Biological Regulation, vol. 54, no. 1, pp. 112–120, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Liang, M. Nagahashi, E. Y. Kim et al., “Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer,” Cancer Cell, vol. 23, no. 1, pp. 107–120, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. Q. Liu, X. Zhao, F. Frissora et al., “FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma,” Blood, vol. 111, no. 1, pp. 275–284, 2008. View at Publisher · View at Google Scholar · View at Scopus
  99. R. Mani, Y. Mao, F. W. Frissora et al., “Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia,” Leukemia, 2014. View at Publisher · View at Google Scholar
  100. N. Zhang, Y. Qi, C. Wadham et al., “FTY720 induces necrotic cell death and autophagy in ovarian cancer cells: a protective role of autophagy,” Autophagy, vol. 6, no. 8, pp. 1157–1167, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Baldacchino, C. Saliba, V. Petroni et al., “Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720,” EPMA Journal, vol. 5, no. 1, article 3, 2014. View at Publisher · View at Google Scholar
  102. G. Marvaso, A. Barone, N. Amodio et al., “Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro,” Cancer Biology & Therapy, vol. 15, no. 6, pp. 797–805, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. S. Buddaseth, W. Göttmann, R. Blasczyk, and T. Huyton, “Overexpression of the pp32r1 (ANP32C) oncogene or its functional mutant pp32r1Y140H confers enhanced resistance to FTY720 (Finguimod),” Cancer Biology and Therapy, vol. 15, no. 3, pp. 289–296, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. M. S. McDermott, B. C. Browne, N. T. Conlon et al., “PP2A inhibition overcomes acquired resistance to HER2 targeted therapy,” Molecular Cancer, vol. 13, p. 157, 2014. View at Google Scholar
  105. S.-Y. Park, M.-H. Moon, J.-K. Jeong et al., “Antiobesity activity of a sphingosine 1-phosphate analogue FTY720 observed in adipocytes and obese mouse model,” Experimental and Molecular Medicine, vol. 44, no. 10, pp. 603–614, 2012. View at Publisher · View at Google Scholar · View at Scopus
  106. C. R. Bruce, S. Risis, J. R. Babb et al., “The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice,” Endocrinology, vol. 154, no. 1, pp. 65–76, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. T. Maki, R. Gottschalk, N. Ogawa, and A. P. Monaco, “Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720,” Transplantation, vol. 79, no. 9, pp. 1051–1055, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. H. Moon, J. Chon, J. Joo et al., “FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice,” Diabetes/Metabolism Research and Reviews, vol. 29, no. 1, pp. 19–24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. T. Imasawa, K. Koike, I. Ishii, J. Chun, and Y. Yatomi, “Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic β-cells,” Biochemical and Biophysical Research Communications, vol. 392, no. 2, pp. 207–211, 2010. View at Publisher · View at Google Scholar · View at Scopus